IP Library Granted Patent US 7,385,032
Granted Patent B2
US 7,385,032 · App. 10/185,425 · Granted Jun 10, 2008

Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins

Assignee: Apotech Research and Development Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,385,032
App. No.
10/185,425
Granted
Jun 10, 2008
Kind
B2
Abstract

The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. The oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence.

Claims (12)

1. A recombinant fusion protein having at least one component A and at least one component B, wherein component A comprises an extracellular segment of FasL protein capable of binding to the Fas receptor and component B comprises a protein segment of ACRP30 comprising the collagen-like segment of ACRP30 without the globular head domain of ACRP30, which oligomerizes the recombinant fusion protein without the effect of third molecules, and wherein said recombinant fusion protein comprises a linker sequence between component A and component B.

2. A DNA sequence that encodes the fusion protein according to claim 1 .

3. An oligomer of the recombinant fusion protein of claim 1 .

4. A recombinant fusion protein having at least one component A and at least one component B, wherein component A comprises an extracellular segment of FasL protein capable of binding to the Fas receptor and component B comprises a protein segment of ACRP30 comprising the collagen-like segment of ACRP30 without the globular head domain of ACRP30, which oligomerizes the recombinant fusion protein without the effect of third molecules, wherein component B comprises amino acids 18 to 111 of mACRP30, or amino acids 18 to 108 of hACRP30.

5. An oligomer of the fusion protein of claim 4 .

6. A DNA sequence that encodes the fusion protein of claim 4 .

7. A recombinant fusion protein having at least one component A and at least one component B, wherein component A comprises an extracellular segment of FasL protein capable of binding to the Fas receptor and component B comprises a protein segment of ACRP30 comprising the collagen-like segment of ACRP30 without the globular head domain of ACRP30, which oligomerizes the recombinant fusion protein without the effect of third molecules, wherein component A is amino acids 139-261 of hFasL.

8. An oligomer of the fusion protein of claim 7 .

9. A DNA sequence that encodes the fusion protein of claim 7 .

10. A recombinant fusion protein having at least one component A and a least one component B, wherein component A comprises amino acids 139-261 of hFasL and component B comprises amino acids 18-111 of mACRP30 or amino acids 18 to 108 of hACRP30.

11. An oligomer of the fusion protein of claim 10 .

12. A DNA sequence that encodes the fusion protein of claim 10 .

Assignments (3)
CHANGE OF NAME Recorded Nov 4, 2010
From: APOTECH RESEARCH AND DEVELOPMENT LIMITED
To: APOXIS SA
Reel/Frame 025313/0447 →
CHANGE OF NAME Recorded Nov 4, 2010
From: APOXIS SA
To: TOPOTARGET SWITZERLAND SA
Reel/Frame 025313/0725 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2002
From: TSCHOPP, JURG; SCHNEIDER, PASCAL; HOLLER, NILS
To: APOTECH RESEARCH AND DEVELOPMENT LTD.
Reel/Frame 013384/0153 →
Priority Claims (1)
DE 199 63 859 · Dec 30, 1999 · national
Continuity (2)
Continuation PCTEP001303200 · Dec 20, 2000
Related Publication 20030053984A1 · Mar 20, 2003